AC Immune Announces Upcoming Presentations at AD/PD™ 2024
- Multiple presentations at the
International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) Andrea Pfeifer , Ph.D., CEO to leadAC Immune -sponsored symposium on alpha-synuclein pathologies
Lausanne,
Industry Symposium: State-of-the-art of treatment and diagnosis of alpha-synuclein pathologies
Session Date/Time:
Opening and Closing Remarks:
Recent developments in the diagnosis of synucleinopathies
Presenter: Werner Poewe, M.D. (
Time: 8:45 –
Development of an a-syn-PET tracer for alpha-synucleinopathies
Presenter:
Time: 9:10 –
New therapeutic approaches in Parkinson's disease
Presenter:
Time: 9:25 –
Morphomer a-syn: small molecules targeting a-syn for the treatment of PD
Presenter:
Time: 9:45 –
Active immunotherapy ACI-7104.056 in early PD: update from the Phase 2 trial VacSYn
Presenter: Nuno Mendonça, M.D. (
Time: 10:05 –
Oral Presentations
Utility of [18F]PI-2620 PET in clinical trials: insights into tau pathology deposition in Down Syndrome
Presenter:
Session: Therapeutic targets in AD: Tau proteins
Date/Time:
Targeting TDP-43 with a vectorized full-length antibody decreases neuropathology in a model of ALS/FTD
Presenter: Damien Nevoltris, Ph.D. (
Session: FTD, ALS: TDP-43, C9ORF72 and TMEM106B 02
Date/Time:
Discovery and preclinical development of [18F]ACI-19626, a first-in-class TDP-43 PET tracer
Presenter: Tamara Seredenina, Ph.D. (
Session: FTD, ALS: TDP-43, C9ORF72 and TMEM106B 02
Date/Time:
VacSYn study: An innovative biomarker-based phase 2 clinical trial to evaluate ACI-7104.056, a novel active immunotherapy for Parkinson’s disease
Presenter: Dymitr Kostrica, M.D. (
Session: Advances in PD and LBD drug development
Date/Time:
Poster Presentations
Anti-Abeta liposomal vaccine, ACI-24.060, retains memory in aggressive mouse model of Alzheimer’s disease
Poster number: P0215 / #1422
Presenter:
Discovery and optimization of novel potent brain penetrant NLRP3 inhibitors
Poster number: P0114 / #1470
Presenter: Tamara Seredenina, Ph.D. (
ACI-7104.056, an active immunotherapy for synucleinopathies, induces a strong and sustained antibody response against alpha-synuclein in non-human primates
Poster number: P0996 / #1513
Presenter:
About
SupraAntigen® is a registered trademark of
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
SVP, Investor Relations & Corporate Communications Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com | U.S. Investors Phone: +1 212 915 2577 Email: cdavis@lifesciadvisors.com |
International Media Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments, and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Attachment
- 20240222_ACIU_ADPD Curtain Raiser updated FINAL
Source:
2024 GlobeNewswire, Inc., source